SAO PAULO (Reuters) – Brazil has absolutely permitted the COVID-19 vaccine developed by Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:), its well being regulator stated on Tuesday, although a dispute over a provide deal means it has none to begin an immunization program with.
It is the primary coronavirus shot to obtain full approval in Brazil, regulator Anvisa stated. Vaccines developed by AstraZeneca (NASDAQ:) and China’s Sinovac Biotech Ltd, have solely been permitted for emergency use.
The approval is sweet news for a rustic whose immunization marketing campaign has been stricken by delays and political squabbling. However, it’s unclear whether or not this can pave the best way for a provide deal of a extremely efficient shot that’s being rolled out globally.
“We hope to be able to move forward in our negotiations with the Brazilian government to support the immunization of the country’s population,” Pfizer’s Brazil boss Marta Diez stated in a press release, with out giving additional particulars.
Brazil’s Health Ministry didn’t reply to a request for remark.
President Jair Bolsonaro has criticized the phrases of a deal proposed by Pfizer, saying it’s overly onerous because it exempts the U.S. agency from potential legal responsibility for unexpected issues. Pfizer has stated different international locations, together with Brazil’s neighbors in Latin America, have agreed to these phrases.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or injury because of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote indicators contained inside this website. Please be absolutely knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is likely one of the riskiest funding kinds doable.